Zusammenfassung
Beim Behandlungsregime der Hochdosis-Chemotherapie erhalten die Patienten gegenüber der konventionellen Dosierung eine Chemotherapie in bis zu 10 facher Dosis, und zur anschließenden Regeneration des Blutbildes wird eine Stammzelltransplantation durchgeführt. Diese Therapie wurde zunächst bei Leukämie- und Lymphompatienten eingesetzt, später jedoch zunehmend auch bei soliden Tumoren. In den vergangenen 15 Jahren wurden immer häufiger auch Mammakarzinompatientinnen mit einer Hochdosis-Chemotherapie und autologer peripherer Stammzelltransplantation (HD-CT) behandelt. Der therapeutische Effekt dieser Hochdosistherapie wird jedoch seit Jahren kontrovers diskutiert. Gerade beim Mammakarzinom war ein enormer Anstieg in der Anwendung der HD-CT zu verzeichnen. In einer Publikation des Autologous Blood and Marrow Transplant Registry of North America (ABMTR) wurde über 5800 Mammakarzinompatientinnen berichtet, die zwischen 1989 und 1995 mit HD-CT behandelt und transplantiert worden waren (Antman et al, 1997). Hier zeigte sich, dass der Anteil Mammakarzinompatientinnen an allen registrierten Transplantationen von 16% im Jahre 1989 auf 40% im Jahre 1995 angestiegen war.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
Literatur
Antman KH, Rowlings PA, Vaughan WP, Pelz CJ, Fay JW, Fields KK, Freyetes CO, Gale RP, Hillner BE, Holland HK, Kennedy MJ, Klein JP, Lazarus HM, McCarthy PL Jr., Saez R, Spitzer G, Stadtmauer EA, Williams SF, Wolff S, Sobocinski KA, Armitage JO, Horowitz MM High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. Journal of Clinical Oncology 1997; 15:1870-1879.
Antman KH. A critique of the eleven randomised trials of high-dose chemotherapy for breast cancer (review). European Journal of Cancer 2001; 37:173-179.
Bezwoda WR. Randomised, controlled trial of high dose chemotherapy (HD-CNV/p) versus standard dose (CAF) chemotherapy for high risk, surgically treated, primary breast cancer. Journal of Clinical Oncology 1999; 17, No. 11s, 21d.
Crump M, Goss PE, Prince M, Girouard C. Outcome of extensive evaluation before adjuvant therapy in woman with breast cancer and 10 or more positive axilliary lymph nodes. Journal of Clinical Oncology 1996; 14: 66-69.
Farquhar C, Marjoribanks J, Basser R, Lethaby A. High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with early poor prognosis breast cancer. The Cochrane Data Base of Systematic Reviews 2008, Volume 2.
Garcia-Carbonero R, Hidalgo M, Paz-Ares L, Calzas J, Gomez H, Guerra JA, Hitt R, Hornedo J, Colomer R, Cortes-Funes H Patient selection in high-dose chemotherapy trials: Relevance in high-risk breast cancer. Journal of Clinical Oncology 1997; 15:3178-3184.
Lancet. Chaos surrounds high-dose chemotherapy for breast cancer. Lancet 1999; 353:1633.
Peters WP. High-dose chemotherapy with autologous bone marrow transplantation for the treatment of breast cancer: Yes. In: DeVita VT, Hellmann S, Rosenberg, SA (Eds.). Important Advances in Oncology, pp 215-230. Philadelphia: Lippincott; 1995.
Peters WP, Dansey R, Klein J, Berry D. High-dose chemotherapy for high-risk primary breast cancer. In: Salomon SE (Ed.). Adjuvant Therapy of Cancer VIII, pp 117-122. Philadelphia: Lippincott; 1997.
Peters W, Rosner G, Vredenburgh J, Shpall E, Crump M, Richardson P, Marks L, Cirrincione C, Wood W, Henderson I, Hurd D, Norton L for CALGB, SWOG and NCIC. A prospective, randomized comparison of two doses of combination alkylating agents (AA) as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes: Preliminary results of CALBG 9082/SWOG 9114/NCIC MA-13. Journal of Clinical Oncology 1999; 17, No. 11s, 21b.
Rahman ZU, Frye DK, Buzdar A, Smith TL, Asmar L, Champlin RE, Hortobagyi GN. Impact of selection process on response rate and long-term survival of potential highdose chemotherapy candidates treated with standard-dose doxirubicin-containing chemotherapy in patients with metastatic breast cancer. Journal of Clinical Oncology 1997; 15:3171-3177.
Rettig RA, Jacobson PD, Farquhar CM, Aubry WM. False hope: Bone marrow transplantation for breast cancer. Oxford University Press, 2007.
Rodenhuis S, Richel DJ, van der Wall E, Schornagel JH, Baars JW, Koning CCE, Peterse JL, Borger JH, Nooijen WJ, Bakx R, Dalesio O, Rutgers E. Randomized trial of highdose chemotherapy and haematopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph node involvment. Lancet 1998; 352: 515-521.
Schmoor C, Olschewski M, Schumacher M. Randomized and non-randomized patients in clinical trials: Experiences with Comprehensive Cohort Studies. Statistics in Medicine 1996; 15:263-271.
Schmoor C, Schumacher M. Methodological arguments for the necessity of randomized trials in high-dose chemotherapy for breast cancer. Breast Cancer Research and Treatment 1999; 54:31-38.
Smith GA, Henderson IC. High-dose chemotherapy (HDC) with autologous bone marrow transplantation (ABMT) for the treatment of breast cancer: The jury is still out. In: DeVita VT, Hellmann S, Rosenberg, SA (Eds.). Important Advances in Oncology, pp 201-214. Philadelphia: Lippincott; 1995.
The Scandinavian Breast Cancer Study Group 9401. Results from a randomized adjuvant breast cancer study with high dose chemotherapy with CTCb supported by autologous bone marrow stem cells versus dose escalated and tailored FEC therapy. Journal of Clinical Oncology 1999; 17, No. 11s, 21c.
Weiss RB, Rifkin RM, Stewart FM, Theriault RL, Williams LA, Herman AA, Beveridge RAl.. High-dose chemotherapy for high-risk primary breast cancer: an on-site review of the Bezwoda study. Lancet 2000; 355:999-1003.
Zander AR, Schmoor C, Kröger N, Krüger W, Möbus V, Frickhofen N, Metzner B, Berdel WE, Koenigsmann M, Thiel E, Wandt H, Possinger K, Kreienberg R, Schumacher M, Jonat W. Randomized trial of high-dose adjuvant chemotherapy with autologous hematopoietic stem-cell support versus standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: Overall survival after 6 years of followup. Annals of Oncology 2008, 19: 1082-1089.
Zujewski J, Nelson A, Abrams J. Much ado about not ... enough data: High-dose chemotherapy with autologous stem cell rescue for breast cancer. Journal of the National Cancer Institute 1998; 90:200-209.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Schumacher, M., Schmoor, C. (2008). Zur Notwendigkeit randomisierter Studien: Hochdosis-Chemotherapie beim Mammakarzinom. In: Methodik klinischer Studien. Statistik und ihre Anwendungen. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-85136-3_2
Download citation
DOI: https://doi.org/10.1007/978-3-540-85136-3_2
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-85135-6
Online ISBN: 978-3-540-85136-3
eBook Packages: Life Science and Basic Disciplines (German Language)